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ABSTRACT 
Introduction:  In October 2010 the Stratified Medicines Innovation Platform (SMIP) 
was created under the oversight of the Technology Strategy Board (TSB) to help 
accelerate the rate of development and uptake of stratified medicine in the UK.  The 
SMIP aim to bring together the private sector, policymakers and researchers in an 
initiative drawing on government funding of over £50 million, along with matched 
funding from industry the total investment might be in the order of £100 million for 
innovative research and development.  The ultimate goal of the SMIP is to accelerate 
the development and uptake of stratified research in the UK and thus make the UK a 
world leader in the development and adoption of stratified medicines.    
Study Objectives:  The primary objective of the research project is to determine if the 
current scientific environment in the United Kingdom is contributing to the (1) 
development and (2) adoption of stratified medicine.  The secondary objective is to 
determine which of the key factors required for the development and adoption of 
stratified medicine is experienced by the key stakeholders to be the biggest obstacles 
in the current scientific environment. 
Methods:   A qualitative assessment were conducted via a questionnaire which was 
distributed to the attendees of the 7th Annual Clinical Outsourcing & Partnering World 
Europe and Disruptive Innovation in Clinical Trials Conferences on the 4th and 5th of 
March 2014 at the Victoria Plaza in London.      
Results and discussion:  The study sample size was the 251 attendees of the 
conferences and the respondents the 48 who completed their questionnaire and return 
it.  The results indicated that a more senior and experienced individual attended the 
conferences.  Nobody with less than 5 years of experience attended.  The overall 
majority (85%) of respondents had 10 or more years of experience in their respective 
industries.   
The primary objective assessed the respondent’s level of agreement with statements 
that the current scientific environment in the UK is contributing to the development and 
adoption of stratified medicine in the UK.  A high score was indicative of a higher level 
of agreement with the relevant statement.  There was a significant difference in the 
average for development at 6.9 (σ = 1.5) and adoption at 3.7 (σ = 1.6).  The 
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respondents were definitely of the opinion that the environment in the UK is more 
favourable for the development than adoption of stratified medicine.   
The secondary objective was to determine which key factors are the most and least 
obstructive for the development and adoption of stratified medicine in the UK.  The 
most obstructive key factors for both development and adoption had in common the 
lack of communication and collaboration among the respective stakeholders, and the 
financial environment which is not contributing to for the development and adoption of 
stratified medicine.  The least obstructive key factors for both development and 
adoption were the science, the scientist ability and knowledge to development and 
adopt stratified medicine.    
Conclusion:  The outcome of the primary measurement clearly indicates that the 
respondents definitely assessed the environment in the UK to be much more 
conducive for the development of stratified medicine than for the adoption of stratified 
medicine.  The average score for development being 6.9 (σ = 1.5) compare to 3.7 (σ = 
1.6) for adoption.  
Limitation:  The conferences focused on outsourcing, partnering and disruptive 
innovation, which is processes and building blocks required for stratified medicine, but 
the focus on stratified medicine could have been more concentrated if the conferences 
were exclusively addressing stratified medicine.  Secondly the project would have 
benefitted from distributing the questionnaires at regular intervals over a period of 
time.  The first distribution should have occurred as close as possible to the SMIP 
launch in October 2010.  This would have allowed the researcher to explore any 
trends that might have revealed it. 
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LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
ABPI  Association of the British Pharmaceutical Industry 
SMIP  Stratified Medicines Innovation Platform 
TSB  Technology Strategy Board 
UK  United Kingdom 
NICE  National Institute for Health and Clinical Excellence 
MRC  Medical Research Council 
 
Stratified medicine: 
The ability to classify individuals into subpopulations that differ in their susceptibility to 
a particular disease or their response to a particular treatment” (ABPI White Paper 
2009). 
 
Qualitative research: 
Research dealing with phenomena that are difficult or impossible to quantify 
mathematically, such as beliefs, meanings, attributes, and symbols. 
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1 INTRODUCTION 
The last few decades has seen a significant number of new medicines and treatments 
discovered and developed by the pharmaceutical industry and approved for patient 
use by the regulatory authorities.  The Association of the British Pharmaceutical 
Industry (ABPI) believes that driving more rapid progress in the adoption of disease 
stratification and personalized medicine could make a significant contribution to 
improving the cost effectiveness and precision of the pharmaceutical research and 
development process.  The healthcare community in the United Kingdom (UK) has 
subsequently over the last number of years identified stratified medicine (“the ability to 
classify individuals into subpopulations that differ in their susceptibility to a particular 
disease or their response to a particular treatment”, ABPI White Paper 2009) as one of 
the key areas where significant gains can be made for the benefit of the patients and 
providing a more cost effective healthcare system (Technology Strategy Board, 2011).  
The Stratified Medicines Innovation Platform (SMIP) was created in October 2010 
under the oversight of the Technology Strategy Board (TSB) to help accelerate the 
rate of development and uptake of stratified medicine in the UK.  The SMIP is a five 
year partnership program that aim to facilitate a series of activities at national level to 
address the challenges of stratified medicine for the benefit of business, healthcare 
providers and the wider economy.  The SMIP aim to bring together the private sector, 
policymakers and researchers in an initiative drawing on government funding of over 
£50 million over the next five years, along with matched funding from industry the total 
investment might be in the order of £100 million for innovative research and 
development (Mansell, 2010).  Competitions were launched in January 2011 for the 
best proposals for funding.   
The TSB has also signed up seven public and charity sector organizations who have 
agreed to work together and combine resources.  The partners are the TSB, the 
National Institute for Health and Clinical Excellence (NICE), Arthritis Research UK, 
Cancer Research UK (CRUK), Scottish Executive Health Directorate, Department of 
Health England and the Medical Research Council (MRC).  These bodies will 
variously supply funding, expertise, advice, research support and infrastructure to help 
move the initiative forward. 
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The ultimate goal of the SMIP is to accelerate the development and uptake of stratified 
research in the UK and thus make the UK a world leader in the development and 
adoption of stratified medicines.  
The rational for this study is to assess if the SMIP (and the associated competitions 
and funding) provided the necessary profile in the healthcare community and 
motivation to create the environment in the UK for the development and adoption of 
stratified medicine over the last few years.  
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2 LITERATURE REVIEW 
Robert Langreth and Michael Waldholz were the first to announce the “New Era of 
Personalized Medicines” (Langreth, 1999), that will treat people based on their 
individual genetic makeup in the Wall Street Journal in 1999.  They were however only 
the first to coin the phrase “Personalized Medicines”, but more individualized 
pharmacotherapy was already undertaken during the 1960 and 1970 with the 
discovery of the oestrogen receptor, and the introduction of the anti-oestrogen 
tamoxifen.  Some success were achieved since 1999, most notably in the field of 
oncology (Trusheim, 2007), but the wider adoptions in pharmacotherapy and funding 
of treatment have not yet materialized.   
Currently the search terminology “stratified medicine” will reference more than 15,000 
hits on Pubmed (http://www.ncbi.nlm.nih.gov/pubmed/?term=stratified+medicine).  
The literature search for this report has focused on publication reporting specifically on 
the activities of the SMIP and the TSB, both of which organizations aim to accelerate 
the rate of development and uptake of stratified medicine in the UK.   
Several publications preceded the formation of the SMIP.  These articles were 
published in the build up to the formation of the SMIP and set some of the key 
milestone and scientific foundations leading to the formation.  The Academy of 
Medical Sciences, Roche and GE Healthcare (2007) addressed some the scientific 
and economic issues regarding the optimization of stratified medicine.  Blair. Clarke 
and O’Neill (2008) adjusted these scientific and economic arguments specific for the 
development of stratified medicine in United Kingdom.  Cressey (2011) reported on 
the first pilot project led by the charity Cancer Research UK which conducted a mass 
screening of various types of cancer tumors in the UK.  Under this program data on 
the tumor samples and the patients from whom they came was analyzed in a national 
database.  This pilot program was part of a wider movement in the UK leading towards 
the development and adoption of stratified medicine in the UK.     
The publication PharmaTimes (http://www.pharmatimes.com/AboutUs.aspx) reported 
on the SMIP from its formation in October 2010 (Mansell, 2010), and provided ongoing 
reporting of the SMIP activities (Mansell, 2011), funding and progress (Megget, 2011).  
The journalist Peter Mansell was responsible for the majority of the PharmaTimes 
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articles.  The researcher had the pleasure of meeting Mr Mansell at the targeted 
conference (7th Annual Clinical Outsourcing & Partnering World and Disruptive 
Innovation in Clinical Trials) and discussed the progress of the SMIP.  
The Technology Strategy Board (2010) released an Output Document reporting on the 
workshop held in 2010.  During this workshop some of the key factors required for the 
development and adoption of stratified medicine were identified.  They also discussed 
some of the collaborative models between pharmaceutical companies and diagnostic 
companies that had been successful in the past.  One of the key issues highlighted 
during this workshop was the need for networking and team work between academics 
and the industry to successfully develop stratified medicine.  The Technology Strategy 
Board (2011) subsequently ran two road mapping workshops in May and June of 2011 
to accelerate the development and uptake of stratified medicine in the UK.  The UK 
Pharmacogenetics and Stratified Medicine Network (2012) were also established and 
subsequently funded by Innovate UK through the Knowledge Transfer Network to 
further support UK world leadership in the development of stratified medicine.    
Trusheim (2011) addressed the co-development of a drug with a diagnostic and 
clarified the key factors required for the development and subsequent adoption of 
stratified medicine.  They also illustrated the influence of these key factors on the 
economic feasibility of stratified medicine and how this impact on public policy makers.    
 
Based on these publications the researcher subsequently formulated seven key 
factors required for the development and adoption of stratified medicine and 
conducted a qualitative assessment, via a questionnaire, on the attendees of the 7th 
Annual Clinical Outsourcing & Partnering World Europe and Disruptive Innovation in 
Clinical Trials Conferences. 
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3 RATIONALE AND BACKGROUND 
Since 2009 stratified medicine has began to attract substantial public and private 
research and development investment.  Progress made in the last five years has been 
possible through the creation of strong alliances within the industry due to the creation 
of the SMIP.  The researcher aimed to assess the progress made over the last few 
years within the UK healthcare community to achieve the aims of the SMIP to develop 
and subsequent adoption of stratified treatment methods.   
The researcher was invited to present at the 7th Annual Clinical Outsourcing & 
Partnering World, Europe conference in London, and with the permission of the event 
organizers (Health Network Communication) distributed a questionnaire to the 
delegates.  The aim of the questionnaire was to conduct a qualitative assessment of 
how the attendees experience the healthcare environment is contributing to the 
development and adoption of stratified medicine in the UK.  The conference was held 
on the 4th and 5th of March 2014 at the Victoria Plaza in London. 
 
4 RESEARCH QUESTIONS AND OBJECTIVES  
4.1 Primary study objective 
The primary objective of the research project is to determine if the current scientific 
environment in the United Kingdom is contributing to the (1) development and (2) 
adoption of stratified medicine.   
4.2 Secondary study objective 
The secondary objective is to determine which of the key factors required for the 
development and adoption of stratified medicine is experienced by the key 
stakeholders to be the biggest obstacles in the current scientific environment. 
 
5 METHODS 
A qualitative assessment were conducted with a questionnaire which was distributed 
to the attendees of the 7th Annual Clinical Outsourcing & Partnering World Europe and 
Disruptive Innovation in Clinical Trials Conferences on the 4th and 5th of March 2014.   
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5.1 Methodology 
The distributed questionnaire consisted out of 5 sections.   
Section 1 consists out of four questions which assess the respondent’s experience in 
their respective industry, in their current role, collect some detail regarding their role 
and which stakeholder group the respondent represent.  
Section 2 consists out of three questions assessing the respondent’s prior involvement 
with stratified medicine. 
Section 3 consists out of two questions assessing the respondent’s opinion of the 
current scientific environment in the UK, and how this is contributing to the 
development and adoption of stratified medicine respectively. 
Sections 4 and 5 list the respective key factors that impact on the development and 
adoption of stratified medicine, and asks the respondents to rate the factors from least 
to most obstructive.  The key factors for each respective process (development and 
adoption) were selected from the literature utilized (Technology Strategy Board, 2010 
and 2011) 
The 7th Annual Clinical Outsourcing & Partnering World Europe (in Victoria Suite 1) 
and Disruptive Innovation in Clinical Trials Conferences (in Victoria suite 2) were held 
in parallel at the Victoria Plaza, London on the 4th and 5th of March 2014.  The study 
questionnaires were distributed during lunch, as a chair drop, on day two in both the 
Victoria Suite 1 (to the attendees of the 7th Annual Clinical Outsourcing & Partnering 
World Europe sessions) and Suite 2 (to the attendees of the Disruptive Innovation in 
Clinical Trials sessions).  As the delegates returned from lunch they were asked to 
complete the study questionnaire and leave the completed questionnaire on their 
seats as they leave for the afternoon tea break.     
5.2 Study population 
The study population can be defined as the healthcare community with an interest or 
are working in the pharmaceutical industry in the UK.  
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5.3 Study sample 
All attendees of the 7th Annual Clinical Outsourcing & Partnering World Europe and 
Disruptive Innovation in Clinical Trials Conferences were allowed to participate and 
complete a study questionnaire.  The study sample is therefore defined as all the 
delegates at said conferences, which were 251.  
5.3.1 Inclusion criteria 
The following inclusion criteria were applied: 
o All attendees (including the speakers) of the 7th Annual Clinical Outsourcing & 
Partnering World Europe conference on the 4th and 5th of March 2014. 
o All attendees (including the speakers) of the Disruptive Innovation in Clinical Trials 
conference on the 4th and 5th of March 2014. 
5.3.2 Exclusion criteria 
The following exclusion criterion was applied: 
o Personnel from the event organizer (Health Network Communications) were asked 
not to complete a study questionnaire. 
o The audio visual production team for the conferences was asked not to complete a 
study questionnaire. 
5.4 Data collection  
Data were collected on the study questionnaire (appendix 2) as approved by WITS 
Ethics (appendix 1).  The speakers allowed about 5 to 7 minutes prior to the start of 
the presentations for the delegates to complete the questionnaires. 
 
6 RESULTS AND DISCUSSION 
The study sample size was the 251 attendees of the two conferences and the 
respondents the 48 attendees who completed and returned their questionnaires. 
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6.1 Demography 
The first two questions collected more information about the experience of the 
individual completing the questionnaire.  It addresses the experience of the 
respondent in their respective industries (question 1.1) and how many years 
experience the respondent has in their current role (question 1.2). 
Question 1.1:  How many years of experience do you have in your industry? 
Participants could choose one from five experience levels in years, starting at 0 to 5 
years increasing in multiple of 5 years.  The results are listed in Table 1.     
Table 1:  Years of experience in industry 
Experience  0 ‐ 5 yrs  5 ‐ 10 yrs  10 ‐ 15 yrs  15 ‐ 20 yrs  20 yrs + 
Respondents  0  7  16  15  10 
%  NA  15%  33%  31%  21% 
n = 48 
The results indicated that a more senior or experienced individual attended the 
conferences.  Nobody with less than 5 years of experience attended.  The overall 
majority, 85% (33% + 31% + 21%) of respondents, had 10 or more years of 
experience in their respective industries.  This is as expected for a conference that 
concentrated on outsourcing and partnering.  The same apply for disruptive innovation 
in the pharmaceutical industry.  These activities are normally undertaken by more 
experienced employees, or individuals in senior decision making positions in their 
respective industries.      
Graph 1 illustrates the experience of the respondents in their respective industries in a 
pie chart format.  
 Graph 1:  Years experience in your industry 
 
Question 1.2 addressed the level of experience the respondents have in their current 
role. 
Question 1.2:  How many years of experience do you have in your current role? 
Participants could choose one from five experience levels in years, starting at 0 to 2 
years increasing in multiple of 2 years.  The results are listed in Table 2. 
Table 2:  Years of experience in current role 
Experience  0 ‐ 2 yrs  2 ‐ 4 yrs  4 ‐ 6 yrs  6 ‐ 8 yrs  8 yrs + 
Respondents  7  18  15  4  4 
%  15%  38%  31%  8%  8% 
n = 48 
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 The level of experience of the respondents in their current role is more evenly 
distributed than the experience level of respondents in their respective industries.  
There is however clearly more respondents with less experience (4 years or less, 
groups 0 to 2 years and 2 to 4 years, which represent 53% of respondents) than 6 
years or more (groups 6 to 8 years and 8 years plus, which represent 16% of 
respondents).   
 
Graph 2 illustrates the experience of the respondents in their current role in a pie chart 
format. 
Graph 2:  Years experience in your current role. 
 
It is difficult to draw a definitive conclusion from this uneven distribution between the 
levels of experience of respondents in their current role.    
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6.2 Primary objective measurements 
The primary objective of this research project was to assess if the attendees at the 
selected two conferences experience the scientific environment in the UK was 
contributing to the (1) development and (2) adoption of stratified medicine.  Due to the 
different key factors required for development and for adoption, these two processes 
were explored and analysed separately.  Questions 3.1 and 3.2 assessed these two 
processes respectively.    
For both questions 3.1 and 3.2 a statement was provided for which the attendees 
were asked to indicate their level of agreement.  A score of 1 indicated that you 
strongly disagree and 10 that you strongly agree with the provided statement. 
The results for question 3.1 (addressing development) is listed in Table 3.  
Question 3.1:   
“The current scientific environment in the United Kingdom is contributing to the 
development of stratified medicine.” 
(1 = I strongly disagree  and  10 = I strongly agree)   
Table 3:  Current scientific environment in UK contributing to the development 
of stratified medicine. 
Number of respondents 41 
Sum 284.5 
Average 6.9 
Standard deviation (σ) 1.5 
 
The results for question 3.2 (addressing adoption) is listed in Table 4. 
Question 3.2:  “The current scientific environment in the United Kingdom is 
contributing to the adoption of stratified medicine.” 
(1 = I strongly disagree  and  10 = I strongly agree)   
 Table 4:  Current scientific environment in the UK contributing to the adoption 
of stratified medicine. 
Number of respondents 41 
Sum 151.5 
Average 3.7 
Standard deviation (σ) 1.6 
There was a significant difference in the average for development at 6.9 (σ = 1.5) and 
adoption at 3.7 (σ = 1.6).  The respondents were clearly of the opinion that the 
environment in the UK is more favourable for the development than adoption of 
stratified medicine.  Graph 3 compares the averages in a bar chart format. 
Graph 3:  Average score for development and adoption for all the respondents. 
 
Graph 4 and 5 contain more detail and provide the number of respondents for each 
response score for development and adoption. 
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 Graph 4:  Scientific environment in the UK is contributing to the development of 
stratified medicine. 
 
Graph 5:  Scientific environment in the UK is contributing to the adoption of 
stratified medicine. 
 
There is an obvious and significant difference between development and adoption, in 
both the averages as well as the distribution of the individual scores for each process.    
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93% (38 out of 41) of the respondents rated the scientific environment in the UK to be 
contributing to the development of stratified medicine with a score of 6 or higher.  For 
the adoption of stratified medicine only 17% (7 out of 41) of the respondents scored 
the environment 6 or higher. 
70% (29 out of 41) of the respondents rated the scientific environment in the UK to be 
contributing to the adoption of stratified medicine with a score of 4 or lower.  For the 
development only 5% (2 out of 41) of the respondents scored the environment 4 or 
lower. 
It is also interesting to note that no respondent scored the scientific environment as 
contributing to the adoption with a score higher than 7.   
A plausible reason for the higher average and concentration of higher scores for 
development of stratified medicine by the respondents is because development 
correlates directly with research and development in the pharmaceutical industry.  The 
respondents are well familiar with those functions as a significant number of 
respondents have research and development responsibilities.  The development of 
stratified medicine, and development as a process is also more introspective within 
the pharmaceutical industry and less dependent on collaboration, or at most a limited 
number of carefully selected external partners.  Adoption of stratified medicine only 
occurs after the development processes have been completed and the acceptance of 
evidence based outcomes and results.  A regulatory authority and numerous 
independent groups, which were unlikely to have been involved during the 
development process, are required to endorse and adopt the relevant new stratified 
treatment regimen.  This is a more complex process with require change from the 
current accepted procedure and might also encounter vested interest to not change.  
There is also less control over the adoption process than there is during the 
development process. 
A second reason for the significant difference might be the slower pace at which 
regulatory authorities adjust to new development or treatment regimens in the 
pharmaceutical market.  New stratified treatment might have been developed, but the 
delay in evaluating and adopting new treatment regimens is probably expressed by 
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the respondents as a more negative perception of the scientific environment in the UK 
regarding the adoption of stratified medicine.  
6.3 Secondary objective measurements 
The secondary objective of this research report was to determine which of the key 
factors required for the development and adoption of stratified medicine was 
experienced to be the biggest obstacles in the current scientific environment.  Due to 
different key factors required for development and for adoption, these two processes 
will be explored and analysed separately. 
Questions 4.1 and 5.1 provided a list of known key factors required for the 
development and adoption of stratified medicine.  Questions 4.2 and 5.2 gave the 
respondents the opportunity to provide additional key factors if they were of the 
opinion not all factors were addressed in the lists provided with questions 4.1 and 5.1.    
Question 4.1: 
Please rate below mentioned established key factors according to their obstacle value 
in the development of stratified treatment options in the UK.   
(rating of 1 = least obstructive, rating of 10 = most obstructive) 
The responders could choose from the following key factors required for the 
development of stratified medicine. 
  Key Factors 
Availability of suitable technology and engineering  
Sufficient skill base in certain medical disciplines 
The lack of a collaborative relationship across the healthcare industry 
The lack of an approach of prediction and prevention in the healthcare industry 
The current reimbursement environment 
The lack of communication and dialogue between regulatory authorities 
Challenges in the assessment of clinical effectiveness of stratified medicine 
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The results for question 4.1 (addressing the key factors require for development) are 
listed in Table 5. 
Table 5:  Key factors required for the development of stratified medicine. 
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Three key factors scored lower than 5, and are therefore considered to be the least 
obstructive.  The remaining four factors all scored higher than 6 and are considered to 
be the more obstructive key factors.  It is noticeable that the three least obstructive 
factors (listed below) all have technology or technical ability in common.  
• Availability of suitable technology and engineering, score of 3.5. 
• Sufficient skill base in certain medical disciplines, score of 3.6. 
• Challenges in the assessment of clinical effectiveness of stratified medicine, 
score of 4.1. 
 This indicates that respondents were of the opinion that the technology to develop 
stratified medicine is not considered an insurmountable obstacle.   
 The remaining four factors that scored a higher obstacle value all have in common the 
lack of communication, collaboration and effective transfer of information among the 
respective key stakeholders.  
Graph 6 present the key factors required for development from least obstructive to 
most obstructive in a bar chart format.      
Graph 6:  Factors that impact development of stratified medicine (lease to most 
obstructive). 
 
Only 6 respondents provided additional key factors as requested in questions 4.2.  
These are listed below with the obstacle value in brackets. 
• NHS (10) 
• Admin red tape (8) 
• Cost (no value) 
• Diagnostic procedure for validation (3.5) 
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• Not enough useful research generic code to identify patient stratification (7) 
• Not enough collaboration between big/med pharm and diagnostic companies to 
develop (7) 
 
Question 5.1 provided the list of known key factors required for adoption and asked 
the respondents to assign obstacle value to each. 
Question 5.1:   
Please rate below mentioned established key factors according to their obstacle value 
in the adoption of stratified treatment options in the UK.   
(rating of 1 = least obstructive, rating of 10 = most obstructive) 
The responders could choose from the following key factors required for the 
development of stratified medicine. 
Factors 
The lack of the required skill base in health economics and associated skills 
The lack of an approach of prediction and prevention healthcare approach 
Increased treatment complexity is not reimbursed for the healthcare provider 
A focus on short term cost and not long term savings 
The lack of a collaborative relationship across the different stakeholders 
The lack of a robust link between evaluation and procurement 
The lack of an accurate assessment and valuation of stratified medicine and the 
companion diagnostic 
 
The results for question 5.1 (addressing the key factors required for adoption) are 
listed in Table 6. 
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Table 6:  Key factors required for the adoption of stratified medicine 
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Respondents  37  37  36  37  37  37  37 
Average  3.6  6.5  7.3  7.2  7.9  6.4  4.1 
Standard 
deviation 
1.6  1.6  1.3  1.5  1.2  1.2  1.7 
 
Based on the average obstacle value the key factors can be divided into two clearly 
defined groups.  The less obstructive group scoring lower than 5, and the more 
obstructive group scoring higher than 6.  It is noticeable that the two least obstructive 
factors (listed below) all have technology or technical ability in common.  Similar to the 
least obstructive factors required for the development of stratified medicine.    
• The lack of the required skill base in health economics and associated skills, 
score 3.6. 
• The lack of an accurate assessment and valuation of stratified medicine and 
the companion diagnostic, score 4.1. 
Graph 7 present the key factors required for adoption from least obstructive to most 
obstructive in a bar chart format. 
 Graph 7:  Factors that impact adoption of stratified medicine (least to most 
obstructive). 
 
The remaining four factors that scored a higher obstacle value all have in common the 
lack of communication, collaboration and effective transfer of information between the 
respective stakeholders involved in the adoption of stratified medicine. 
Only 2 respondents provided additional key factors as requested in questions 5.2.  
These are listed below with the obstacle value in brackets. 
• NHS (10) 
• Admin red tape (8) 
 
The least obstructive three key factors for development and the two least obstructive 
key factors for adoption is similar in the sense that it can be interpreted that “the 
sciences and scientist is not the problem”. 
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The most obstructive key factors for both development and adoption all have in 
common the lack of communication and collaboration and the financial environment 
that is not contributing to for the development and adoption of stratified medicine. 
 
7 CONCLUSION 
The outcome of the primary measurement clearly indicates that the respondents 
definitely assess the environment in the UK to be much more favourable for the 
development of stratified medicine than for the adoption of stratified medicine.  The 
average score for development is 6.9 (σ = 1.5) compare to 3.7 (σ = 1.6) for adoption, 
where the higher average indicate an agreement from the respondents that the 
environment in the UK is contributing to either development or adoption.   
The secondary measurement clearly indicated the respondents assessed the science, 
the scientist ability and knowledge were the least obstructive factors for both 
development and adoption processes of stratified medicine.  The three least 
obstructive factors for development were (1) availability of suitable technology and 
engineering, (2) sufficient skill base in certain medical disciplines and (3) challenges in 
the assessment of clinical effectiveness of stratified medicine.  The two least 
obstructive factors for adoption were (1) the lack of the required skill base in health 
economics and associated skills and (2) the lack of an accurate assessment and 
valuation of stratified medicine and the companion diagnostic.  All of these least 
obstructive factors for both development and adoption have science (ability and 
knowledge) as a common factor.  The secondary measurement also clearly identified 
a common factor for the most obstructive key factors for both development and 
adoption as the lack of communication, collaboration and effective information sharing 
among the key stakeholders. 
The secondary measurement outcomes (science is the least obstructive factors for 
both development and adoption) therefore support the primary measurement outcome 
(the environment is more favourable for the development than for adoption) because 
the science is integral for the development of stratified medicine.  The secondary 
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measurement outcomes provide further support by indicating that communication, 
collaboration and effective information sharing is the most obstructive key factors, all 
of which is essential for the adoption of stratified medicine.      
The primary and secondary measurement outcomes thus indicate that the scientific 
environment is the UK is more favourable for the development of stratified medicine 
than for the adoption.  The highest rated obstructive key factors are all related to 
adoption and not development.  
 
8 LIMITATIONS 
The project had the following limitations and shortcomings. 
8.1 Sample selection 
The selected sample could have been more representative and focused on the 
scientific environment in the UK regarding stratified medicine if the following conditions 
could have been met.  
The conference held on the 4th and 5th of March 2014 at the Park Plaza Victoria in 
London also had attendees from outside of the UK.  This might have only been a 
relative small number of attendees, but it still diluted the focus of the responses which 
was as a result not exclusively focused to the scientific environment only in the UK.   
The conferences focus on outsourcing, partnering and disruptive innovation, which is 
process and building blocks required for stratified medicine, but the focus on stratified 
medicine could have been more concentrated if the conferences were exclusively 
focused on stratified medicine. 
8.2 Study design 
The project could have been more representative of the study population if the study 
questionnaire were distributed at more than two parallel run conferences.  The project 
would have benefitted from distributing the questionnaires at regular intervals.   The 
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first sample should have been taken as close as possible to the SMIP launch in 
October 2010.  An annual distribution at an appropriate conference would have 
allowed the researcher to identify and explore any trends that might have revealed it.     
 
9 RECOMMENDATIONS 
The researcher has made the following recommendations for future projects regarding 
the development and adoption of stratified medicine in the UK.  
o It is highly recommended that more and dedicated time is allowed for the 
conference attendees to complete the questionnaire.  This will result in more 
attendees responding and a more representative sample. 
o If more time is available to complete the questionnaire it would also be 
recommended that questions addressing and exploring solutions of how to improve 
the environment for the development and adoption of stratified medicine are 
included in the questionnaire. 
o It would be highly beneficial to collaborate with the SMIP in projects of this nature 
in the future.  The SMIP might be sensitive regarding the specific questions, but 
the benefits of working with the SMIP and conductive objective research should 
prevail.      
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 Development and adoption of stratified medicine questionnaire  
 
1. Questions about the individual and who you represent. 
 
1.1. How many years of experience do you have in your industry? 
0  - 5yrs 5 – 10yrs 10 – 15yrs 15 – 20yrs 20yrs + 
     
 
 
1.2. How many years of experience do you have in your current role? 
0  - 2yrs 2 – 4yrs 4 – 6yrs 6 – 8yrs 8yrs + 
     
 
 
1.3. How would you describe your current role? 
 
 
 
 
1.4. Which stakeholder do you represent? (Mark all that apply) 
Academia 
(you are primarily engaged in higher education and research) 
 
Industry  
(biotechnology, pharmaceutical, contract research organisation, vendor or diagnostic 
company)  
 
Healthcare professional  
(doctor, nurses, pharmacists and other providers of healthcare to patients) 
 
Healthcare regulator  
(ethics committee, regulatory authority or other healthcare regulatory capacity) 
 
Other  
(please provide details)................................................................................................. 
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2. Questions regarding your involvement in the United Kingdom stratified medicine 
initiatives. 
 
Please draw a circle around your response.  
 
2.1. Have your heard or work with the UK Technology Strategy Board (TSB)? Yes    /    No  
 
2.2. Have you heard or work with the Stratified Medicine Innovation Platform (SMIP) Yes    /    No 
 
2.3. Are you aware that the SMIP is a five-year programme that aim to accelerate 
the development and uptake of stratified medicine in the UK?   Yes    /    No 
 
 
 
 
3. Questions assessing your opinion of the current scientific environment in the United 
Kingdom. 
 
3.1. Please indicate your level of agreement with the below mentioned statement. 
1 = I strongly disagree  and  10 = I strongly agree.   
 
“The current scientific environment in the United Kingdom is contributing to 
the development of stratified medicine.” 
 
My response  =  ..................... 
 
 
3.2. Please indicate your level of agreement with the below mentioned statement.  
1 = I strongly disagree  and  10 = I strongly agree.   
 
“The current scientific environment in the United Kingdom is contributing to 
the adoption of stratified medicine.” 
 
My response  =  ..................... 
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4. Your experience of which key factors impact on the DEVELOPMENT of stratified medicine 
in the United Kingdom. 
 
4.1. Please rate below mentioned established key factors according to their obstacle value  in 
the development of stratified treatment options in the UK. 
(rating of 1 = least obstructive, rating of 10 = most obstructive) 
Key Factors 
Obstacle 
value 
Availability of suitable technology and engineering   
Sufficient skill base in certain medical disciplines  
The lack of a collaborative relationship across the healthcare industry  
The lack of an approach of prediction and prevention in the healthcare industry  
The current reimbursement environment  
The lack of communication and dialogue between regulatory authorities  
Challenges in the assessment of clinical effectiveness of stratified medicine  
 
 
4.2. Please provide any other key factors that impact on the DEVELOPMENT of stratified 
medicine in the UK and assign an obstacle value. 
(rating of 1 = least obstructive, rating of 10 = most obstructive) 
Key Factors 
Obstacle 
value 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
__________________________________________________________________________ 
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5. Your experience of which key factors impact on the ADOPTION of stratified medicine in the 
United Kingdom. 
 
5.1. Please rate below mentioned established key factors according to their obstacle value  in 
the adoption of stratified treatment options in the UK. 
(rating of 1 = least obstructive, rating of 10 = most obstructive) 
Factors 
Obstacle 
value 
The lack of the required skill base in health economics and associated skills  
The lack of an approach of prediction and prevention healthcare approach  
Increased treatment complexity is not reimbursed for the healthcare provider  
A focus on short term cost and not long term savings  
The lack of a collaborative relationship across the different stakeholders  
The lack of a robust link between evaluation and procurement  
The lack of an accurate assessment and valuation of stratified medicine and 
the companion diagnostic 
 
 
5.2. Please provide any other key factors that impact on the ADOPTION of stratified medicine in 
the UK in order of their obstacle value.  
(rating of 1 = least obstructive, rating of 10 = most obstructive) 
Factors 
Obstacle 
value 
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INFORMATION DOCUMENT  
 
Study title: An assessment if the current scientific environment in the United 
Kingdom is contributing to the development and adoption of stratified 
medicines. 
 
 
Dear Sir / Madam 
 
Introduction: 
I am doing research on the development and adoption of stratified medicine in the UK.  
In this study I want to learn about the factors that impact on the development and 
adoption of stratified medicine in the UK.   
 
 
Invitation to participate:   
As a participant at the 7th Annual Clinical Outsourcing & Partnering World, and 
Disruptive Innovation in Clinical Trials conference, I am asking you to please complete 
the attached questionnaire consisting out of 13 questions.   
 
 
What is involved in the study: 
If you choose to participate you would be required to complete the attached 
questionnaire.  It consists out of 13 questions and should take approximately 5 minutes to 
complete.  The questionnaire asks about your experience in the clinical research industry 
and your perception of factors impacting on the development and adoption of stratified 
medicine in the UK.    
 
 
Participation is voluntary: 
Refusal to participate will involve no penalty or loss of benefits which you might receive 
as attendee of this conference.   
 
 
Reimbursements:   
You will not be reimburse to complete the questionnaire. 
 
 
Confidentiality:  
No personal identification information is collected and no effort will be made to identify 
any individual that completed the questionnaire.    
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